Dechra Pharmaceuticals PLC

Half Year Presentation 2022

Improving

Global Animal

Health and

Welfare

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.

Our Purpose is the sustainable improvement of global animal health and welfare.

For more information please visit www.dechra.com

Companion Animal Products (CAP)

Species: Dogs and cats.

Key therapeutic sectors: Endocrinology, dermatology, analgesia and anaesthesia, antibiotics, cardiovascular, critical care and oncology.

Equine

Species: Horses and ponies.

Key therapeutic sectors: Lameness and pain management.

Food producing Animal Products (FAP)

Species: Poultry, pigs and an increasing presence in cattle.

Key therapeutic sectors: Water soluble antibiotics, vaccines, locomotion (lameness) and pain management.

Nutrition

Species: Dogs and cats.

Key therapeutic sectors: Our pet diets are available to support the wellbeing of cats and dogs with numerous

therapeutic conditions, such as allergies, obesity, heart and kidney disease.

Operational Highlights

We continue to outperform a market that has seen strong growth

Portfolio Focus

a b c

  • All product categories and major therapeutic areas delivering strong growth
  • H1 benefit from increased COVID-19 spending on pets

Pipeline Delivery

• Good progress continues

• New opportunities under review

Geographic Expansion

• International businesses performed well

  • Robust performance from distribution business supplemented by new product launches
  • Successfully launched Tri-Solfen in ANZ

Acquisition

• Executed six product acquisitions

  • Majority strengthen our North American business
  • Laverdia expands portfolio into oncology

®

3

Operational Highlights

Strategic Enablers

Technology

• Digital technology continues to be main strategic focus

  • Commenced work on a new quality management system
  • Approved investment to move most of manufacturing sites onto one consolidated ERP System

Manufacturing

and Supply

  • Supply chain robust and supporting high levels of growth
  • Completed our exit from third party manufacturing at Skipton and Fort Worth
  • Expanded Danish distribution centre to open in April 2022

People

  • The cornerstone of our success
  • Alison Platt appointed Chair of the Board
  • Strengthened Senior Management Team

Environmental, Social and Governance

  • Decarbonisation remains top priority
  • Employee engagement via inaugural Dechra Climate Race

®

4

Financial Highlights

Strong revenue growth delivering operating leverage

Revenue Growth

  • 15.9% to £332.4 million
  • Predominately driven by organic growth

Underlying

EBIT Growth

  • 22.0% to £93.9 million
  • Lower R&D spend in H1, expected to correct in H2

Operating Cash

Generation

• 110.0% underlying cash conversion

Shareholders'

Value

  • Underlying diluted EPS +24.0% increase to 64.01 pence
  • Interim dividend: +8.0% increase to 12.00 pence

In presentation all financial references will be at CER unless otherwise stated.

®

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Dechra Pharmaceuticals plc published this content on 21 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 February 2022 10:50:02 UTC.